SECsense Logo

Adial Pharmaceuticals, Inc. 8-K Filing Report: Key Updates as of January 13, 2025

$ADIL
Form 8-K
Filed on: 2025-01-13
Source
Adial Pharmaceuticals, Inc. 8-K Filing Report: Key Updates as of January 13, 2025

Based on the provided section of the financial report, here are the key pieces of information extracted:

  1. Entity Information:
  • Company Name: Adial Pharmaceuticals, Inc.
  • CIK Number: 0001513525
  • SEC File Number: 001-38323
  • EIN: 82-3074668
  • Address: 4870 Sadler Road, Ste 300, Glen Allen, VA 23060
  • Phone Number: 804-487-8196
  1. Report Type:
  • Filing Type: 8-K
  • Filing Date: January 13, 2025
  1. Context Information:
  • Report Date: January 13, 2025 (the report is as of this date)
  • Period Start Date: January 13, 2025
  • Period End Date: January 13, 2025
  1. Units of Measure:
  • Currency: USD (United States Dollar)
  • Shares: The report includes information regarding shares, but specific data points such as share count or price are not provided in this excerpt.
  1. Stock Information:
  • Common Stock Symbol: ADIL
  • Exchange: NASDAQ

Summary Insights:

  • Adial Pharmaceuticals, Inc. filed an 8-K report on January 13, 2025, indicating a significant event or information to disclose to investors.
  • The company is publicly traded under the ticker symbol ADIL on the NASDAQ exchange.
  • The filing does not include detailed financial metrics or share counts, which would typically be present in a more comprehensive report.

This information is crucial for investors and analysts monitoring Adial Pharmaceuticals for corporate governance, potential investment opportunities, or regulatory compliance updates.